Northern Trust Corp purchased a new stake in shares of Orchard Therapeutics PLC – (NASDAQ:ORTX) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 36,811 shares of the company’s stock, valued at approximately $579,000.
Several other hedge funds have also recently bought and sold shares of ORTX. Massachusetts Financial Services Co. MA bought a new stake in shares of Orchard Therapeutics in the 4th quarter valued at about $6,948,000. Dean Capital Investments Management LLC bought a new stake in shares of Orchard Therapeutics in the 4th quarter valued at about $674,000. Finally, Victory Capital Management Inc. bought a new stake in shares of Orchard Therapeutics in the 4th quarter valued at about $106,000. 56.65% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:ORTX opened at $20.07 on Tuesday. Orchard Therapeutics PLC – has a one year low of $8.65 and a one year high of $21.64. The stock has a market capitalization of $1.74 billion and a PE ratio of -1.96.
ORTX has been the subject of several recent research reports. Wedbush restated an “outperform” rating and issued a $25.00 price target on shares of Orchard Therapeutics in a report on Friday, March 22nd. Zacks Investment Research lowered shares of Orchard Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 2nd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Orchard Therapeutics currently has an average rating of “Buy” and a consensus target price of $23.40.
COPYRIGHT VIOLATION WARNING: “36,811 Shares in Orchard Therapeutics PLC – (ORTX) Acquired by Northern Trust Corp” was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.thelincolnianonline.com/2019/05/07/36811-shares-in-orchard-therapeutics-plc-ortx-acquired-by-northern-trust-corp.html.
About Orchard Therapeutics
Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.
Featured Article: How to interpret the current ratio
Want to see what other hedge funds are holding ORTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orchard Therapeutics PLC – (NASDAQ:ORTX).
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.